PRX-07034

{{Short description|Chemical compound}}

{{Drugbox

| verifiedrevid = 424987327

| IUPAC_name = N-[1-(5-chloro-2,3-dimethoxyphenyl)ethyl]-2-methylsulfonyl-5-piperazin-1-ylaniline

| image = PRX-07034.svg

| tradename =

| legal_status = Uncontrolled

| routes_of_administration = Oral

| CAS_number = 903580-16-5

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = YJ5TMF911R

| ATC_prefix = none

| PubChem = 11532574

| ChemSpiderID = 9707357

| C=21 | H=29 | Cl=2 | N=3 | O=4 | S=1

| smiles = COc2cc(Cl)cc(c2OC)C(C)Nc1cc(ccc1S(=O)(=O)C)N3CCNCC3

| StdInChI = 1S/C21H28ClN3O4S/c1-14(17-11-15(22)12-19(28-2)21(17)29-3)24-18-13-16(25-9-7-23-8-10-25)5-6-20(18)30(4,26)27/h5-6,11-14,23-24H,7-10H2,1-4H3

| StdInChIKey = BSLXKMCHXRCBIH-UHFFFAOYSA-N

}}

PRX-07034 is a selective 5-HT₆ receptor antagonist.{{cite web | url = http://sciencelinks.jp/j-east/article/200617/000020061706A0577975.php | title = Science Links Japan | PRX-07034, a Potent and Selective 5-HT6 Receptor Antagonist, Reduces Food Intake and Body Weight in Rats }} It has cognition and memory-enhancing properties and potently decreases food intake and body weight in rodents.{{cite journal | author = Fone KC | title = An update on the role of the 5-hydroxytryptamine6 receptor in cognitive function | journal = Neuropharmacology | volume = 55 | issue = 6 | pages = 1015–22 |date=November 2008 | pmid = 18655798 | doi = 10.1016/j.neuropharm.2008.06.061 | s2cid = 35522597 }}{{cite web | url = http://sciencelinks.jp/j-east/article/200617/000020061706A0578001.php | title = Science Links Japan | Combination of sub-threshold doses of Aricept and PRX-07034, a novel 5-HT6 receptor antagonist, enhances Novel Object Discrimination (NOD) memory }}{{cite journal | vauthors = Halford JC, Harrold JA, Boyland EJ, Lawton CL, Blundell JE | title = Serotonergic drugs : effects on appetite expression and use for the treatment of obesity | journal = Drugs | volume = 67 | issue = 1 | pages = 27–55 | year = 2007 | pmid = 17209663 | doi = 10.2165/00003495-200767010-00004 | s2cid = 46972692 | url = https://dx.doi.org/10.2165%2F00003495-200767010-00004 | access-date = 2010-03-09 | archive-url = https://archive.today/20130105064850/http://content.wkhealth.com/linkback/openurl?issn=0012-6667&volume=67&issue=1&spage=27 | archive-date = 2013-01-05 | url-status = dead | url-access = subscription }} PRX-07034 was under development by Epix Pharmaceuticals for the treatment of obesity and cognitive impairment associated with Alzheimer's disease and schizophrenia but upon the company collapsing due to lack of funds the compound was auctioned to another corporation.{{cite web | url = http://investorshub.advfn.com/boards/read_msg.aspx?message_id=11491017 | title = PREDIX Pharmaceuticals (PRDX): Fourth Predix drug candidate enters clinical trials }}{{cite web | url = http://pr.gaeatimes.com/epix-pharmaceuticals-inc-announces-a-successful-auction-sale-of-five-drug-program-intellectual-properties-on-september-30-2009-6816/ | title = Epix Pharmaceuticals, Inc. Announces a Successful Auction Sale of Five Drug Program Intellectual Properties on September 30, 2009 }}{{cite web | url = http://pr.gaeatimes.com/epix-pharmaceuticals-inc-announces-prx-07034-therapeutics-cns-phase-2-will-be-part-of-the-intellectual-property-offered-for-sale-at-the-september-30-2009-auction-4809/ | title = Epix Pharmaceuticals, Inc. Announces PRX-07034 Therapeutics - CNS Phase 2 Will be Part of the Intellectual Property Offered for Sale at the September 30, 2009 Auction }}